文献速递新生儿儿童呼吸儿童感染

家长对新生儿使用尼塞韦单抗的看法

Parent Perspectives on Nirsevimab for Their Newborn.
PubMed 文献 · Pediatrics · 2024-01-01

该研究通过半结构化访谈探讨健康新生儿家长对尼塞韦单抗(nirsevimab)预防呼吸道合胞病毒(RSV)的决策态度,发现38%计划接种、25%不计划、38%不确定,存在知识缺口与错误信息,信任儿科医生建议和恐惧RSV感染促进接种。

要点

  • 家长对RSV预防存在显著知识缺口,且对尼塞韦单抗有错误信息。
  • 信任儿科医生推荐和恐惧RSV感染是促进接种的主要因素。
  • 推迟接种的家长担心副作用、认为母体RSV疫苗足够或信赖自身预防措施。

核心结论

  • 提高对尼塞韦单抗和婴儿RSV的整体认知、孕期开始对话以对抗错误信息、利用与儿科医生和产前临床医生的信任关系有助于未来接种。

主要发现

  • 38%的参与者计划给新生儿使用尼塞韦单抗,25%不计划,38%不确定。
  • 出现了四个主要主题:关于RSV预防存在重大知识缺口;信任儿科医生推荐和恐惧RSV感染促进接种;推迟接种的家长担心副作用、希望更多时间决定、认为母体RSV疫苗足够且信任自身预防措施;家长中存在关于尼塞韦单抗的错误信息,包括认为其是类似COVID-19疫苗的新且研究不足的疫苗。
  • 应用健康信念模型突出了在感知易感性和RSV疾病严重性、益处、障碍、自我效能和行动提示方面影响决策的可操作机会。

临床怎么用

  • 在孕期开始与家长讨论尼塞韦单抗和婴儿RSV,以对抗错误信息。
  • 利用与儿科医生和产前临床医生的信任关系,针对感知易感性、疾病严重性、益处、障碍、自我效能和行动提示进行沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hospitalizations. We sought to better understand how parents of otherwise healthy newborns would respond to this recommendation. METHODS: We conducted semistructured interviews of purposefully sampled parents of newborns admitted to the well newborn unit between November 2023 and February 2024. Interviews were performed in a constant comparative manner until thematic sufficiency was reached using the Health Beliefs Model as a conceptual framework. RESULTS: We conducted 28 interviews: 38% of participants planned to give nirsevimab to their newborn, 25% did not plan to, and 38% were unsure. Four major themes emerged: (1) Major knowledge gaps existed about RSV prophylaxis; (2) trust in pediatrician's recommendation and fear of RSV infection contributed to uptake; (3) parents deferring RSV prophylaxis were concerned about side effects, wanted more time to decide, felt the maternal RSV vaccine was sufficient, and trusted their own prevention measures; and (4) there was misinformation about nirsevimab among parents including a perception that nirsevimab is a new understudied vaccine with similarities to the COVID-19 vaccine. Application of the Health Beliefs Model highlighted actionable opportunities to positively influence decision making around perceived susceptibility and RSV disease severity, benefits, barriers, self-efficacy, and cues to action. CONCLUSIONS: Increasing overall awareness of both nirsevimab and RSV in infants, starting conversations during pregnancy to combat misinformation, leveraging trusting relationships with pediatricians and prenatal clinicians can help with future uptake.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Hinderstein S, Aragona E, Loyal J, et al. Parent Perspectives on Nirsevimab for Their Newborn. Pediatrics. 2024. PMID: 39587878. doi:10.1542/peds.2024-067532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。